We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01492673
First Posted: December 15, 2011
Last Update Posted: April 26, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Genentech, Inc.
Children's Mercy Hospital Kansas City
Penn State University
University of Colorado, Denver
Sidney Kimmel Comprehensive Cancer Center
Phoenix Children's Hospital Center for Cancer & Blood Disorders
Alberta Children's Hospital
MD Anderson Cancer Center Orlando
M.D. Anderson Cancer Center
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2018
  Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)